ArticleOphthalmology science2026
Assessing the Impact of Pharmacological Pupil Dilation on Anterior Chamber Cells Counting Using OCT.
Article in Ophthalmology science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Anterior chamber (AC) cells are seen as hyperreflective dots (HRDs) on anterior segment OCT (AS-OCT), but many factors can affect their objective counting. The aim of this study was to evaluate the effect of pharmacological dilation with tropicamide 0.5% (T) or phenylephrine 2.5% + tropicamide 0.5% (PH + T) on the assessment of AC HRDs density measured in healthy eyes by AS-OCT. Design: Cross-sectional, observational study. Participants: Healthy subjects with no history of uveitis, no ocular or systemic conditions, and no recent ocular surgery. Methods: Participants underwent comprehensive ophthalmic examinations, including single-line AS-OCT (16.5 mm; μm:pixel ratio = 8.79; Anterion, Heidelberg Engineering) imaging before (miosis) and after pupil dilation with either T or PH + T drops. Hyperreflective dots were quantified using FIJI (National Institutes of Health, Bethesda) through the Analyze Particles tool after image binarization. Hyperreflective dot density was calculated by dividing the total HRDs by the AC area and expressed as the number per 10 000 pixels². Iris displacement after dilation was measured using the apex-to-pupil distance (APD). Main Outcome Measures: Anterior chamber HRDs density before and after dilation measured by AS-OCT. A generalized Poisson mixed-effects model was used to evaluate the effects of group (miosis, T, PH + T), lens status (phakic, pseudophakic), and their interaction on HRD density. Covariates included age, sex, iris color, and variation in APD after dilation (APDD). Results: A total of 100 eyes from 59 healthy participants (55.9% female), mean age 73.0 ± 11.7 years were included. Mean (standard deviation) HRDs density (per 10 000 pixels²) significantly increased from 0.79 (1.44) in normal photopic conditions to 1.71 (3.30) after the dilatation in the T group and from 0.52 (0.83) to 15.8 (25.8) in the PH + T group ( Conclusions: Pharmacological dilation, especially with PH + T, significantly increases HRDs in the AC of healthy subjects, with a more pronounced effect in phakic eyes and greater APDD. These findings suggest increased iris-lens friction and potential pigment release after dilation, providing critical considerations for standardizing AS-OCT-based assessments of AC inflammation. Financial Disclosures: The author has no/the authors have no proprietary or commercial interest in any materials discussed in this article.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.